Literature DB >> 26268442

Adverse events during placebo vs. no drug administration--results of a randomised interventional trial in 160 volunteers.

Frank Erbguth1, Angelika Hamacher-Erbguth2, Uwe Fuhr3, Fritz Sörgel4,5.   

Abstract

Mesh:

Substances:

Year:  2015        PMID: 26268442     DOI: 10.1007/s00228-015-1900-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

Review 1.  Do we need a new procedure for the assessment of adverse events in anti-migraine clinical trials?

Authors:  Martina Amanzio
Journal:  Recent Pat CNS Drug Discov       Date:  2011-01

2.  Pretreatment status and its relationship to the length of drying-out period.

Authors:  W Guy; P A Cleary
Journal:  Psychopharmacol Bull       Date:  1976-04

3.  Framing and personalizing informed consent to prevent negative expectations: An experimental pilot study.

Authors:  Sarah R Heisig; Meike C Shedden-Mora; Pablo Hidalgo; Yvonne Nestoriuc
Journal:  Health Psychol       Date:  2015-02-16       Impact factor: 4.267

Review 4.  The nocebo effect and its relevance for clinical practice.

Authors:  Luana Colloca; Franklin G Miller
Journal:  Psychosom Med       Date:  2011-08-23       Impact factor: 4.312

Review 5.  Nocebo and the potential harm of 'high risk' labelling: a scoping review.

Authors:  Andrew Symon; Brian Williams; Qadir A Adelasoye; Helen Cheyne
Journal:  J Adv Nurs       Date:  2015-02-20       Impact factor: 3.187

6.  To tell the truth, the whole truth, may do patients harm: the problem of the nocebo effect for informed consent.

Authors:  Rebecca Erwin Wells; Ted J Kaptchuk
Journal:  Am J Bioeth       Date:  2012       Impact factor: 11.229

Review 7.  Nocebo phenomena in medicine: their relevance in everyday clinical practice.

Authors:  Winfried Häuser; Ernil Hansen; Paul Enck
Journal:  Dtsch Arztebl Int       Date:  2012-06-29       Impact factor: 5.594

8.  Placebo? no thanks, it might be bad for me!

Authors:  Silvio Garattini; Vittorio Bertelé; Rita Banzi
Journal:  Eur J Clin Pharmacol       Date:  2012-09-16       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.